Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
Shinozaki, Eiji, Yoshino, Takayuki, Tsuchihara, KatsuyaLanguage:
english
Journal:
British Journal of Cancer
DOI:
10.1038/s41416-018-0040-y
Date:
March, 2018
File:
PDF, 210 KB
english, 2018